The FDA has accepted Gilead Sciences’ new drug application for a single-tablet, once-daily HIV treatment combination and ...

Prism Health North Texas, a community health center, participated in clinical trials for Merck's new HIV treatment, Idvynso.

Add Yahoo as a preferred source to see more of our stories on Google. A new single-pill HIV treatment has proved as effective as regimens of up to 11 tablets a day in suppressing the virus in ...

Merck is carving out its own place in the evolving HIV treatment space with an FDA approval for its Idvynso, a combination ...

A new study in Health Economics suggests the advent of highly active antiretroviral therapy (HAART) for HIV in 1996 may have unintentionally fueled a resurgence of syphilis in the U.S. Researchers ...

Gilead Sciences, Inc. today announced details of new clinical and real-world data from its innovative HIV treatment and prevention portfolio and research pipeline that will be presented at the 33rd ...

Among the new types of CAR therapies under development are CAR-NK cells, which the authors explained are seen as a ...

Every person with HIV needs treatment for the rest of their life. For some, this means 10 or more drugs taken throughout each day. But as NPR's Gabrielle Emanuel reports, a study shows there's new ...

According to UNAIDS, Senegal is among a few countries in West and Central Africa where new HIV infections have increased in ...

A coalition of advocates are calling on Arkansas lawmakers to decriminalize the sexually transmitted disease and commit ...

– Latest Data from the PURPOSE Program Further Demonstrates the Safety and Efficacy Profile of Twice-Yearly Lenacapavir for HIV Prevention – “Striving for continuous progress in HIV means delivering ...